Featured news
WE-REACH Alum Lutz Lab Awarded $14.9 Million for Rapid COVID Diagnostic Device
WE-REACH Alum Barry Lutz’s Anavasi Diagnostics has been awarded $14.9 million from the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADxSM) initiative. Learn more →
Learn More About WE-REACH: Fact Sheet
Mission
-Leverage public-private partnerships to support end-to-end Innovations for health impact and access
-Accelerate the transformation of novel discoveries into innovative products
-Award milestone-driven WE-REACH R&D projects with value-added services
-Fuel the formation of sustainable start-up companies
-Train the next generation of biomedical entrepreneurs
-Serve as a national REACH innovation hub for the Pacific Northwest donation
FUNDING
Commercialization award and support
TRAINING
Programs for students and faculty
NEWS
Opportunities and announcements
EVENTS
Connect with people and resources
News & Opportunities
$14.9M Awarded to Lutz Lab's COVID-19 Technology CompanyNovember 11, 2021
WE-REACH support helps team pivot from academia to small business ventureNovember 11, 2021
WE-REACH Fall Proposal Due Date Extended to August 9thAugust 6, 2021
Immediate funding opportunity for point-of-care COVID variant testing and more! Deadline June 28June 7, 2021
$14.9M Awarded to Lutz Lab's COVID-19 Technology CompanyNovember 11, 2021WE-REACH support helps team pivot from academia to small business ventureNovember 11, 2021WE-REACH Fall Proposal Due Date Extended to August 9thAugust 6, 2021Immediate funding opportunity for point-of-care COVID variant testing and more! Deadline June 28June 7, 2021
Contact us
Email:
Follow us on Twitter
Support us
Sign up for Newsletter
Our Partners
Partners are founding members or organizations providing funding and support for WE-REACH projects and initiatives.
Collaborators
Collaborators provide value-add services, educational resources, technical support, project pipelines, and other opportunities to ensure the success of WE-REACH initiatives.
WE-REACH is supported in part by NIH Grant #1 U01 HL152401-01 and partners.